Radcliffe Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Radcliffe Capital Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-327,150	Closed	-$3.3M	–	833
2022 Q4	$3.3M	Hold	327,150	–	–	0.1%	307
2022 Q3	$3.24M	Buy	327,150 +27,150	+9%	+$268K	0.08%	433
2022 Q2	$2.94M	Hold	300,000	–	–	0.07%	502
2022 Q1	$2.94M	Hold	300,000	–	–	0.07%	479
2021 Q4	$2.91M	Hold	300,000	–	–	0.08%	421
2021 Q3	$2.91M	Hold	300,000	–	–	0.08%	362
2021 Q2	$2.9M	Buy	+300,000	New	+$2.92M	0.09%	371

Radcliffe Capital Management's IBER Position: Q1 2023 in Review

Radcliffe Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 327,150 shares — an estimated $3.3M sold.

Radcliffe Capital Management first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $3.3M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Radcliffe Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 327,150 Ibere Pharmaceuticals shares in Q1 2023, an estimated $3.3M.
Radcliffe Capital Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Radcliffe Capital Management's Ibere Pharmaceuticals position peaked at $3.3M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.